Abstract
Nilotinib or Dasatinib Front-Line Therapy in Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-existing Liver and/or Renal dysfunction
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have